Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial

Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial

Background: There is a paucity of prospective data for patients who progressed after first-line tyrosine kinase inhibitor (TKI) or pemetrexed doublet among epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small cell lung cancer (NSCLC). Aim: The aim of the study was to evalua...

Full description

Saved in:
Bibliographic Details
Main Authors: Vanita Noronha, Avinash Pandey, Vijay Patil, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2018-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Gefitinib
pemetrexed
second-line lung cancer
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=4;spage=493;epage=498;aulast=Noronha
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=4;spage=493;epage=498;aulast=Noronha

Similar Items